Table 1 Demographics and clinical presentations of the MetS subjects
Characteristic | MetS patients (N = 1000) |
|---|---|
Gender; Male/ Female (N, %) | 466 (46.6%)/ 548 (53.4%) |
COVID-19 cases; Yes/No (N, %) | 206 (20.6%)/794 (79.4%) |
COVID-19 severity; mild/severe (N, %) | 189 (91.8%)/ 17 (8.2%) |
Smoker/ Non-smoker | 484 (48.4%)/516 (51.6%) |
Familial history of CVD (Yes/No) | 149 (14.9%)/ 851 (85.1%) |
Age (Year, mean ± SD) | 51.1 ± 10.9 |
Duration of MetS (Year) | 14.45 ± 8.7 |
Duration of COVID-19 (Day) | 12.5 ± 2.2 |
Oxygen saturation (in COVID-19 cases) | 93.5 ± 5.6 |
Systolic BP (mmHg) | 130.8 ± 22.9 |
Diastolic BP (mmHg) | 73.3 ± 7.1 |
WBC (cells/mm3) | 7378 ± 1814.1 |
Lymphocyte-total leukocyte ratio | 26.8 ± 14.3 |
Neutrophil-lymphocyte ratio | 10.1 ± 12.3 |
ALP (IU/L) | 215.8 ± 44.3 |
AST (IU/L) | 26.1 ± 7.4 |
ALT (IU/L) | 33.1 ± 8.7 |
LDH (IU/L) | 324.8 ± 79.5 |
CRP (mg/L) | 3.5 ± 1.3 |
ESR (mm/h) | 14.8 ± 10.3 |
BMI (kg/m2) | 29.4 ± 5.2 |
WC-Male (cm) | 99.6 ± 14.8 |
WC-Female (cm) | 94.8 ± 13.4 |
Total cholesterol (mg/dl) | 201.7 ± 36.9 |
TG (mg/dl) | 157.1 ± 57.1 |
LDL (mg/dl) | 128.5 ± 37.9 |
HDL (mg/dl) | 49.1 ± 14.1 |
Creatinine (mg/dl) | 1.61 ± 0.39 |
BUN (mg/dl) | 22.7 ± 16.2 |
FBS (mg/dl) | 96.2 ± 28.3 |
Fever (in COVID-19 cases) | 200 (97.1%) |
Cough (in COVID-19 cases) | 197 (95.6%) |
Dyspnea (in COVID-19 cases) | 202 (98.1%) |
Sputum (in COVID-19 cases) | 122 (59.2%) |
Vomiting/diarrhea (in COVID-19 cases) | 118 (57.3%) |
Methylprednisolone use (in COVID-19 cases) | 160 (77.6%) |
Dexamethasone use (in COVID-19 cases) | 163 (79.1%) |
Remdesivir use (in COVID-19 cases) | 99 (48.1%) |
Tocilizumab use (in COVID-19 cases) | 4 (1.9%) |
Cefixime use (in COVID-19 cases) | 36 (17.5%) |
Azithromycin use (in COVID-19 cases) | 24 (11.7%) |